Keye Life, a clinical-stage biotech company, presented its innovative pipeline targeting RNA helicases at the 4th BIONNOVA South China Innovation Forum, held from December 9 to 10 in Guangzhou, China. The forum gathered leading figures from global pharma, top-tier Chinese biopharmaceutical companies, academia, and clinical practice to explore cutting-edge frontiers in drug development.

Dr. Yandong Zhang, Founder of Keye Life, was invited to speak at the "Innovative Discovery of Small Molecules" session. Her presentation, titled "Targeting RNA Helicase DHX33: A Novel Therapeutic Strategy for Advanced Solid Tumors," showcased the company's progress in this emerging field.

Targeting RNA helicases represents a promising yet challenging new avenue in oncology therapeutics. While technical hurdles exist, the significant unmet need and limited competition create substantial potential. Dr. Zhang outlined the biological rationale for targeting the RNA helicase protein family and reviewed the global competitive landscape.

She detailed Keye Life's differentiated approach, focusing on the mechanism of DHX33 and the development path for its novel small-molecule inhibitors. The company's lead DHX33 candidate demonstrated favorable safety and promising drug-like properties in preclinical studies. Dr. Zhang also highlighted the parallel development of a companion diagnostic for this target.

【About Keye Life】

Keye Life is an innovative biotechnology company dedicated to discovering and developing novel therapies targeting RNA helicases for cancers and other serious diseases with high unmet medical needs. The company has built a differentiated pipeline with two clinical-stage assets. Its lead product, KY386 Injection, for advanced solid tumors, is in Phase I trials in China and has received FDA Orphan Drug Designation for hepatocellular carcinoma and gastric cancer. A second product, KY2 Oral Capsule for advanced gastrointestinal cancers, is initiating Phase I studies. A companion diagnostic, KY4 (A001), is also in concurrent Phase I trials.